Alder BioPharmaceuticals, Inc. (ALDR) Rating Reiterated by Mizuho
Mizuho restated their buy rating on shares of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) in a research report report published on Wednesday morning. They currently have a $32.00 price objective on the biopharmaceutical company’s stock.
Several other equities research analysts also recently commented on the company. Zacks Investment Research raised Alder BioPharmaceuticals from a hold rating to a buy rating and set a $13.00 target price on the stock in a report on Tuesday, July 11th. Royal Bank Of Canada started coverage on Alder BioPharmaceuticals in a report on Thursday, September 14th. They set an outperform rating and a $17.00 price target on the stock. Credit Suisse Group set a $11.00 price target on Alder BioPharmaceuticals and gave the company a hold rating in a report on Thursday, August 24th. BidaskClub raised Alder BioPharmaceuticals from a strong sell rating to a sell rating in a report on Friday, August 25th. Finally, Needham & Company LLC set a $36.00 price target on Alder BioPharmaceuticals and gave the company a buy rating in a report on Monday, July 17th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $28.07.
Shares of Alder BioPharmaceuticals (ALDR) opened at $11.15 on Wednesday. Alder BioPharmaceuticals has a 1-year low of $8.60 and a 1-year high of $34.30.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.21) by $0.29. During the same period in the prior year, the company earned ($0.70) earnings per share. sell-side analysts anticipate that Alder BioPharmaceuticals will post -5.36 EPS for the current fiscal year.
In related news, insider Mark James Litton sold 16,520 shares of the company’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $12.33, for a total transaction of $203,691.60. Following the completion of the sale, the insider now owns 116,452 shares in the company, valued at $1,435,853.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in Alder BioPharmaceuticals by 5.5% during the second quarter. Vanguard Group Inc. now owns 3,626,573 shares of the biopharmaceutical company’s stock valued at $41,525,000 after acquiring an additional 187,871 shares during the last quarter. Janus Henderson Group PLC purchased a new stake in Alder BioPharmaceuticals during the second quarter valued at $36,956,000. Redmile Group LLC increased its position in Alder BioPharmaceuticals by 16.4% during the second quarter. Redmile Group LLC now owns 2,223,811 shares of the biopharmaceutical company’s stock valued at $25,463,000 after acquiring an additional 313,925 shares during the last quarter. State Street Corp increased its position in Alder BioPharmaceuticals by 9.4% during the second quarter. State Street Corp now owns 1,944,755 shares of the biopharmaceutical company’s stock valued at $22,267,000 after acquiring an additional 167,642 shares during the last quarter. Finally, BB Biotech AG increased its position in Alder BioPharmaceuticals by 15.2% during the second quarter. BB Biotech AG now owns 1,941,008 shares of the biopharmaceutical company’s stock valued at $22,225,000 after acquiring an additional 255,858 shares during the last quarter. Institutional investors own 78.57% of the company’s stock.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.